Products Rufinamide
Rufinamide Phase 3 Terminated 📈 Rising Refractory Partial Onset Seizures
Refractory Partial Onset Seizures
Mar 15, 2007 → May 14, 2010
About Rufinamide Rufinamide is a phase 3 stage product being developed by Eisai for Refractory Partial Onset Seizures. The current trial status is terminated. This product is registered under clinical trial identifier NCT00448539. Target conditions include Refractory Partial Onset Seizures.
Clinical Trials (4) NCT ID Phase Status Start Completion Indication NCT03778424 Pre-clinical Active — — Lennox Gastaut Syndrome NCT02175173 Pre-clinical Completed Jun 13, 2013 Nov 2, 2022 Lennox-Gastaut Syndrome NCT01151540 Phase 3 Completed Nov 1, 2010 Aug 1, 2013 Lennox-Gastaut Syndrome NCT00448539 Phase 3 Terminated Mar 15, 2007 May 14, 2010 Refractory Partial Onset Seizures
Competing Products 20 competing products in Refractory Partial Onset Seizures
See all competitors Product Company Stage Hype Score Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 agenT-797 MiNK Therapeutics Phase 1 eFT508 + Avelumab eFFECTOR Therapeutics Phase 2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 Valemetostat Tosylate Daiichi Sankyo Phase 2 Enzalutamide Astellas Pharma Phase 2 ASP1650 Astellas Pharma Phase 2 YM598 Astellas Pharma Phase 2 erlotinib + etoposide Astellas Pharma Phase 2 Mitoxantrone Hydrochloride Liposome & Enlonstobart Sun Pharmaceutical Phase 1/2 Lenvatinib + Everolimus Eisai Phase 1/2 perampanel + perampanel + perampanel + Placebo Eisai Phase 3 Eribulin mesilate + Irinotecan hydrochloride Eisai Phase 1/2 perampanel Eisai Phase 2 rabeprazole sodium Eisai Pre-clinical Lenvatinib Eisai Phase 2 E2007 (perampanel) + E2007 (perampanel) + Placebo Eisai Phase 3 E2007 (perampanel) + E2007 (perampanel) + Placebo Eisai Phase 3 Tazemetostat Eisai Phase 2 Lenvatinib + Moxifloxacin 400 mg + Placebos (matched to 4 mg and 10 mg lenvatinib capsules). Eisai Phase 1
Other Products from Eisai